Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. The company is headquartered in Exton, Pennsylvania and currently employs 37 full-time employees. The company went IPO on 2020-10-02. The Company’s primary focus area is oncology. Its discovery platform identifies therapeutic antibodies and their targets by leveraging components of the immune system, memory B cells. The Company’s lead discovery programs include Oncology (IMM-ONC-01) and SARS-CoV-2 (IMM-BCP-01). The Company’s IMM-ONC-01 is its lead oncology program targets interleukin 38 (IL-38), which is a negative regulator of inflammation capable of promoting tumor evasion of the immune system. The firm is developing an antibody cocktail derived from the B cells of COVID-19 patients who exhibited high neutralizing titers. IMM-BCP-01 targets non-overlapping regions of the Spike protein of SARS-CoV-2, which include highly conserved, subdominant epitopes. The IMM-BCP-01 program is focused on the variants of SARS-CoV-2.